All lectures introduced by Dr Maarten van Dongen
International experts will provide their up-to-date vision on the topics
Ample room for Q&A during the sessions.
|09:30||Introduction: AMR, misunderstood, global phenomenon|
|A closer acquaintance with the participants and short introduction to the Masterclass. How AMR is viewed from different sectors and how we communicate about AMR? Do we understand each other when we talk about AMR?|
||Bacteria: desperately needed and detested
Dr Amine Zorgani; S-Biomedic, Beerse (Belgium)
|What are bacteria? What kind of pathogenic bacteria are there and how do they spread? But also: what function do they have, what diseases in humans, animals and plants can they cause? And what about viruses, fungi, yeasts and parasites?|
||Antibiotics: desperately needed but also cause of AMR
Dr Rohini Wadanamby; Lanka hospital, Colombo (Sri Lanka)
|What are antibiotics? How were they discovered and how do they work? What (classes of) antibiotics are there and what do they protect against? How are new antibiotics developed and why don’t we see novel ones on the market?|
|11:30||Antibiotic resistance & AMR: get the overall picture
Dr Charles Lam; Lam Consulting, Vienna (Austria)
|What are antibiotic resistance and AMR? How do they originate and spread around the world? Why are they threatening our health and food safety: what are the statistics, socio-economic implications and consequences for public health?|
|A short reflection on the morning program and room for questions and comments. If time permits, we will discuss case studies of the participants.|
|01:15||WHO Global & national Action Plans: momentum is vital|
|What does the Global Action Plan entail? What is the set-up and how does the plan ad to curbing AMR? How does WHO cooperate with FAO and OIE. What is the role for individual countries & EU? And (how) does the UN monitor this?|
|01:45||Key strategies to tackle AMR: the One Health perspective|
|We explain the 5 equally important key strategies in the One Health perspective. We show how the different strategies reinforce each other to ultimately lead to an effective global control. And address their global challenges.|
|02:00||1: Prevention Infections: why so underestimated?
Prof Ziad Daoud; Michigan Health Clinics, Michigan (USA)
|Preventing infections results in the decreased use of antibiotics and prevents (resistant) bacteria from spreading. What is the impact of good sanitation, hygiene and use of disinfectants as well as of vaccination of humans and animals on AMR.|
||2: Antibiotic Stewardship: worldwide feasible?
Anita E. Asamoah MPH; Public Health Epidemiologist/Researcher (Ghana)
|Monitoring the use of antibiotics reduces the risk of AMR. When and by whom are antibiotics prescribed? How disturbing are “illegal” illegal antibiotics sales? May these be used as animal growth promoters in animals and in citrus cultivation?|
||3: Microbial Diagnostics: technologies need Darwin?
Prof Till Bachmann; University of Edinburgh, Edinburgh (UK)
|Diagnostics help to identify patients and to set the proper therapy. Diagnostics distinguish bacteria from viruses (where antibiotics do not work), identify bacteria (such that the proper antibiotics are being administered) and may determine the antibiotics sensitivity. Do we use diagnostics properly and do we use proper diagnostics? What scientific developments are there and will new diagnostic tools reach the market?|
||4: Novel Antibiotics: can we restore a broken market?
Dr Jeroen Bakker; NOVO Holdings, Copenhagen (Denmark)
|New antibiotics, to which bacteria are still sensitive, are increasingly needed in the global fight against AMR. Why is this, and why fewer new antibiotics appear on the market? Can we break this trend and what role is played by CARB-X, GARDP and the Global AMR R&D Hub. What’s in for biotech and big pharma?|
||The Environment & AMR: reducing antibiotic emissions?
Nicolai Schaaf; SIWI, Stockholm (Sweden)
|Antibiotics in effluents from hospitals and antibiotics producers, in surface (waste) water and in the environment lead to the emergence and spread of resistant bacteria. These can end up in the human food chain. Especially in LMICs, where people may wash themselves in surface waters, this leads to contamination with resistant bacteria. What can we do about this and can we pay for this?|
|04:30||COVID-19: more AMR but less attention?|
|Corona has unprecedentedly raised the global awareness that infectious diseases can have pandemic proportions. Although COVID-19 so far has resulted in less victims than AMR in the same time period, AMR is clearly driven into the background. Meanwhile many COVID-19 inpatients are mistakenly being treated with antibiotics which may result in an increase of AMR.|
||5: Alternative Anti-microbials: room on the markets?
Prof Steffanie Strathdee; University of California, San Diego (USA)
|Alternatives to antibiotics are increasingly important to curb AMR. In addition to the phage therapy, antimicrobial tissue replacers, nanomaterials and probiotics appear to fight (resistant) bacteria without leading to AMR. What are the developments and what are the promises of phage therapy in theory and practice?|
|A short reflection on the afternoon program and room for questions and comments.|